NO20060651L - Fremgangsmate for behandling av virale infeksjoner - Google Patents

Fremgangsmate for behandling av virale infeksjoner

Info

Publication number
NO20060651L
NO20060651L NO20060651A NO20060651A NO20060651L NO 20060651 L NO20060651 L NO 20060651L NO 20060651 A NO20060651 A NO 20060651A NO 20060651 A NO20060651 A NO 20060651A NO 20060651 L NO20060651 L NO 20060651L
Authority
NO
Norway
Prior art keywords
ribavirin
interferon
related compound
administering
day
Prior art date
Application number
NO20060651A
Other languages
English (en)
Norwegian (no)
Inventor
Howard J Smith
Original Assignee
Smith Howard J & Ass Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34193246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060651(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smith Howard J & Ass Pty Ltd filed Critical Smith Howard J & Ass Pty Ltd
Publication of NO20060651L publication Critical patent/NO20060651L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20060651A 2003-08-13 2006-02-09 Fremgangsmate for behandling av virale infeksjoner NO20060651L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49482803P 2003-08-13 2003-08-13
PCT/AU2004/001031 WO2005016370A1 (en) 2003-08-13 2004-08-03 Method of treating viral infections

Publications (1)

Publication Number Publication Date
NO20060651L true NO20060651L (no) 2006-05-02

Family

ID=34193246

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060651A NO20060651L (no) 2003-08-13 2006-02-09 Fremgangsmate for behandling av virale infeksjoner

Country Status (15)

Country Link
US (1) US20070202078A1 (https=)
EP (1) EP1660116A4 (https=)
JP (1) JP2007501806A (https=)
CN (1) CN1835765A (https=)
AR (1) AR045263A1 (https=)
AU (1) AU2004264255A1 (https=)
BR (1) BRPI0413474A (https=)
CA (1) CA2535451A1 (https=)
CL (1) CL2004002030A1 (https=)
IL (1) IL173630A0 (https=)
NO (1) NO20060651L (https=)
NZ (1) NZ545159A (https=)
RU (1) RU2371195C2 (https=)
WO (1) WO2005016370A1 (https=)
ZA (1) ZA200601181B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CN1847256B (zh) * 2005-04-13 2011-06-15 长春华普生物技术有限公司 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用
WO2006131790A2 (en) * 2005-06-09 2006-12-14 Flamel Technologies Oral ribavirin pharmaceutical composition
WO2009031918A1 (ru) * 2007-09-05 2009-03-12 Shatunovsky Nikolai Evgenievic Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с
WO2009046369A2 (en) * 2007-10-05 2009-04-09 Medtronic, Inc. Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
PE20110343A1 (es) * 2008-09-17 2011-06-25 Boehringer Ingelheim Int Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US20130295052A1 (en) 2010-11-19 2013-11-07 Manu Chaudhary Novel conjugates for targeted drug delivery
RU2665638C1 (ru) * 2017-05-24 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3222259A (en) * 1963-10-25 1965-12-07 Ethyl Corp Flare stack with a liquid seal
JPS5439143Y2 (https=) * 1976-04-16 1979-11-20
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
DK1136075T3 (da) * 1997-09-21 2003-04-28 Schering Corp Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
CA2331823A1 (en) * 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
JP2002527522A (ja) * 1998-10-16 2002-08-27 シェリング・コーポレーション 慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法
AR021876A1 (es) * 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
US6962717B1 (en) * 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions
AU4463300A (en) * 1999-04-19 2000-11-02 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
EP1326594A2 (en) * 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
CA2372987A1 (en) * 2001-12-11 2003-06-11 Thomas R. Wiseman Method of disposal of liquid from gas wells

Also Published As

Publication number Publication date
RU2006107566A (ru) 2007-09-20
NZ545159A (en) 2009-03-31
AR045263A1 (es) 2005-10-19
JP2007501806A (ja) 2007-02-01
CN1835765A (zh) 2006-09-20
BRPI0413474A (pt) 2006-10-17
US20070202078A1 (en) 2007-08-30
CA2535451A1 (en) 2005-02-24
RU2371195C2 (ru) 2009-10-27
IL173630A0 (en) 2006-07-05
CL2004002030A1 (es) 2005-06-03
WO2005016370A1 (en) 2005-02-24
EP1660116A4 (en) 2008-04-30
EP1660116A1 (en) 2006-05-31
ZA200601181B (en) 2007-04-25
AU2004264255A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
WO2004002999A3 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
NO20060651L (no) Fremgangsmate for behandling av virale infeksjoner
EP2219642B1 (en) Silibinin component for the treatment of hepatitis
ES2324909T3 (es) Preparado con principio activo en forma de pelicula con mejora de la estabilidad quimica y procedimiento para su fabricacion.
JP2005289996A5 (https=)
BR0316082A (pt) Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit
JP2003506416A5 (https=)
JP2008519047A5 (https=)
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
RU2366450C1 (ru) Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций
WO2014027334A2 (es) Composicion farmacéutica oral en forma de microesferas y proceso de elaboración
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
HUP0303838A2 (hu) Eritropoietin mérsékli a kemoterápia-indukált toxicitást in vivo
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
MXPA05005046A (es) Formulaciones parasiticidas topicas y metodos de tratamiento.
ATE533509T1 (de) Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff
JP2006511538A5 (https=)
EP1609473A8 (en) Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria
WO2004041190A3 (en) Composition for the treatment of macular degenration
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
US20170312297A1 (en) Long Acting Pharmaceutical Compositions For Hepatitis C
WO2003026570A3 (en) Reduced toxicity cisplatin formulations and methods for using the same
Yu et al. Chromoblastomycosis successfully treated with fluconazole.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application